Most Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) owners assume they are buying broad market diversification. The latest Schwab fact sheet tells a different story. SCHD’s top 10 holdings now account for roughly 42% of the fund’s $95.7 billion in net assets, well above the roughly 30% top-10 weight typical of large-cap dividend peers. SCHD still earns its reputation as a low-cost income workhorse, but the concentration question changes who should treat it as a core holding versus a sleeve.
What SCHD is built to do
SCHD tracks the Dow Jones U.S. Dividend 100 Index, which screens for cash flow to debt, return on equity, dividend yield, and five-year dividend growth, then reconstitutes once a year. The screen is the point: it filters out high yielders that cannot sustain payouts and tilts the portfolio toward established cash generators. The return engine is plain. You get dividends from roughly 100 quality-screened companies plus whatever capital appreciation those businesses produce. No options overlay, no leverage, no derivatives.
The expense ratio of 0.06% puts SCHD in the cheapest tier of any dividend ETF, and the trailing yield sits near 3.2% based on recent quarterly distributions, still well above the S&P 500’s roughly 1.3%. The fund has grown its dividend at an annualized rate of about 11.6% over the past five years, which is the kind of compounding that turns a modest starting yield into a much stronger income stream over time.
Does the strategy deliver?
SCHD has returned about 22% year to date through mid-July, outpacing both the S&P 500 and the Nasdaq-100 in 2026. The five-year price gain trails the S&P 500’s roughly 90% over the same window, which is the honest tradeoff: the dividend-quality screen kept SCHD out of the mega-cap tech names that drove most of the index’s gains in recent years. Add a decade of compounded dividends to the 229% ten-year price gain, and the absolute result still works well for income investors.
Through the article’s original publication in June 2026, several top holdings were driving the rebound. ConocoPhillips (NYSE:COP | COP Price Prediction) had surged 29% year to date, Chevron (NYSE:CVX) was up 27%, and Altria (NYSE:MO) was up 26%. Those gains reflect SCHD’s former heavy energy tilt. The March 2026 annual reconstitution changed the picture significantly.
The March 2026 reconstitution and what it means now
The annual index reconstitution, effective March 23, 2026, reshaped SCHD’s top holdings more than any rebalance in recent years. The fund added 25 new names, including UnitedHealth Group, Abbott Laboratories, Procter & Gamble, and Qualcomm, while removing 22 holdings. AbbVie and Cisco Systems both exited the fund entirely. Bristol-Myers Squibb, Lockheed Martin, and Altria remain in the portfolio but dropped out of the top 10.
The sector impact was sharp. Energy exposure fell by roughly 8%, pulling the sector from a near-dominant ~20% weight to closer to 15%. Healthcare climbed to roughly 20% of assets, now the fund’s largest sector. The chart below reflects the December 31, 2025 snapshot used in the original analysis; the post-reconstitution top 10 looks considerably different.
As of July 20, 2026, Schwab’s own holdings page shows Abbott Laboratories leading the fund at 4.59%, followed by UnitedHealth Group at 4.40%, Merck at 4.27%, Amgen at 4.23%, Home Depot at 4.18%, Procter & Gamble at 4.18%, Coca-Cola at 4.10%, Chevron at 3.93%, PepsiCo at 3.74%, and Verizon at 3.65%. The top 10 collectively account for about 41.8% of net assets, essentially unchanged from before the reconstitution in percentage terms. The names inside that concentration, however, shifted toward healthcare and away from energy and tobacco.
The concentration tradeoff
The 42% top-10 weight is a byproduct of the yield-and-quality screen plus annual reconstitution, not a random outcome. The fund holds essentially no real estate and minimal utilities, and it now tilts most heavily toward healthcare and consumer staples. The narrow band among the top holdings means a single-sector shock, whether a major Medicare policy shift affecting UnitedHealth or an Abbott product recall, hits the fund harder than its 100-stock roster would suggest.
Three risks matter for a holder. A healthcare regulatory event or a tobacco regulatory shock now hits the fund harder than an oil-price collapse once did, given the sector reweighting. The absence of meaningful tech exposure means SCHD will continue lagging in markets driven by AI and semiconductors. And annual reconstitution can swap out names in size, generating capital-gains events for holders in taxable accounts. The exits of AbbVie and Cisco in 2026 illustrated this: two large positions unwound in a single rebalance cycle.
Who SCHD still fits
SCHD works as a dividend-growth core for accumulators reinvesting distributions and for retirees who want a rising income stream paired with rock-bottom fees. The $0.26 Q1 2026 distribution is roughly double the $0.12 paid in late 2011, which is the kind of payout growth income investors need to stay ahead of inflation. Abbott Laboratories, UnitedHealth Group, Merck, and the rest of the current top tier now anchor the income engine where AbbVie and Cisco once did.
Investors who already own a total-market or S&P 500 fund can pair SCHD with it cleanly because the dividend screen excludes most of the mega-cap growth names that dominate broad benchmarks. Investors whose entire equity allocation sits in SCHD should add a broad growth or international dividend fund to offset the healthcare and staples concentration that now characterizes the portfolio. Treat SCHD as a high-quality income sleeve that happens to concentrate its bets, and it earns its place. Mistake it for a fully diversified core, and the next sector drawdown will cost more than the dividend pays.
Editor’s note: This update refreshes the fund’s net assets from $71.6 billion to $95.7 billion (as of July 2026), corrects the trailing yield from approximately 3.9% to approximately 3.2%, incorporates the March 2026 annual reconstitution that removed AbbVie and Cisco from the fund and elevated Abbott Laboratories and UnitedHealth Group to the top two positions, and updates the year-to-date return figure and sector allocation to reflect the post-reconstitution portfolio.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks